Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
Open Access
- 31 January 2022
- journal article
- research article
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 39 (1), 62-66
- https://doi.org/10.12701/yujm.2021.00934
Abstract
Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab ((sic), Baize'an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.Keywords
This publication has 17 references indexed in Scilit:
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Stomach cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 studyCancer, 2017
- Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 InhibitorsThe Oncologist, 2017
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015JAMA Oncology, 2017
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Corticotropin-Releasing Hormone and Arginine Vasopressin Gene Transcription in the Hypothalamic Paraventricular Nucleus of Unstressed Rats: Daily Rhythms and Their Interactions with CorticosteroneEndocrinology, 2004
- Hyponatremia and Inappropriate Secretion of Vasopressin (Antidiuretic Hormone) in Patients with HypopituitarismThe New England Journal of Medicine, 1989
- Co-localization of corticotropin releasing factor and vasopressin mRNA in neurones after adrenalectomyNature, 1985